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Abstract
Objectives: To investigate whether APOE e4 carriers have higher hippocampal atrophy rates than non-carriers in Alzheimer’s
disease (AD), mild cognitive impairment (MCI) and controls, and if so, whether higher hippocampal atrophy rates are still
observed after adjusting for concurrent whole-brain atrophy rates.
Methods: MRI scans from all available visits in ADNI (148 AD, 307 MCI, 167 controls) were used. MCI subjects were divided
into ‘‘progressors’’ (MCI-P) if diagnosed with AD within 36 months or ‘‘stable’’ (MCI-S) if a diagnosis of MCI was maintained. A
joint multi-level mixed-effect linear regression model was used to analyse the effect of e4 carrier-status on hippocampal and
whole-brain atrophy rates, adjusting for age, gender, MMSE and brain-to-intracranial volume ratio. The difference in
hippocampal rates between e4 carriers and non-carriers after adjustment for concurrent whole-brain atrophy rate was then
calculated.
Results: Mean adjusted hippocampal atrophy rates in e4 carriers were significantly higher in AD, MCI-P and MCI-S (p#0.011,
all tests) compared with e4 non-carriers. After adjustment for whole-brain atrophy rate, the difference in mean adjusted
hippocampal atrophy rate between e4 carriers and non-carriers was reduced but remained statistically significant in AD and
MCI-P.
Conclusions: These results suggest that the APOE e4 allele drives atrophy to the medial-temporal lobe region in AD.
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Introduction
Hippocampal atrophy rate has been proposed as an imaging
biomarker for Alzheimer’s disease (AD) progression [1,2].
However, it is essential to understand how factors might affect
hippocampal atrophy rates if this biomarker is to be used most
effectively in clinical trials.
Arguably, the most important genetic risk factor for sporadic
AD is the e4 variant of the APOE gene [3]. Of the three common
alleles of the APOE gene, e3 is most frequent with e4 less common
and e2 relatively rare [4]. e4 increases the risk of AD and lowers
the age of disease onset [5]. There is also evidence that the
topography of atrophy in e4 carriers (e4+) may be different from
non-carriers (e4-) in AD [6–9] although not all studies have
confirmed this [10].
Numerous publications have attempted to elucidate whether
APOE modifies hippocampal atrophy rates [11–25]. Although
some studies reported elevated hippocampal atrophy rates in e4+
in AD, mild cognitive impairment (MCI) and control groups, it is
possible that the greater hippocampal rates observed could have
been attributed to higher concurrent whole-brain atrophy rates
and therefore faster disease progression.
To better understand the effect of the APOE e4 allele on the
progression of structural brain changes we wanted to investigate
whether different whole-brain and hippocampal atrophy rates
were observed in e4+ compared with e4- in AD, MCI and
controls. Further, we wanted to investigate if there is evidence of
higher hippocampal atrophy rates in e4+ when adjusting for
concurrent whole-brain atrophy rates, which to our knowledge,
has not been examined.
Methods
Ethics Statement
Data used in preparation of this article were obtained from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
(adni.loni.ucla.edu). ADNI is a multi-centre study with data
collected from over 50 sites. The institutional review board at all
participating sites approved the study and written consent was
obtained from all participants. More information can be found at
http://www.adni-info.org/scientists/Pdfs/
ADNI_Protocol_Extension_A2_091908.pdf.
Subjects
ADNI is a multi-centre public/private funded longitudinal study
investigating adult subjects with AD, amnestic MCI, and normal
cognition. Participants underwent baseline and periodically
repeated clinical and neuropsychometric assessments and MRI.
Subjects from ADNI who had a baseline MRI scan and at least 1
follow-up scan were included in this study. Each subject
underwent APOE genotyping at the screening visit. Detailed
inclusion criteria for the ADNI study can be found at http://www.
adni-info.org/scientists/Pdfs/
ADNI_Protocol_Extension_A2_091908.pdf. All demographic in-
formation, diagnoses, neuropsychological test scores and APOE
genotype data were downloaded from the ADNI clinical data
repository.
Since a proportion of MCI subjects will likely not progress to
dementia caused by AD, this group is likely to be quite
heterogeneous with respect to underlying pathology. As a result,
we dichotomised the MCI subjects into those who were observed
to progress to a clinical diagnosis of AD within 36 months of
baseline and maintained that diagnosis (MCI-P) and those who
were stable over the follow-up period (MCI-S). Subjects whose
diagnosis changed from MCI to AD and subsequently reverted to
MCI during the study were excluded as were subjects whose
diagnosis changed from MCI to normal. e2 carriers (i.e. e2/e2,
e2/e3 and e2/e4 subjects) were also excluded from the study as
they may have lower hippocampal atrophy rates [26]. There were
a total of 840 ADNI subjects available at the time of this study,
after exclusions this number reduced to 622 subjects. The number
of subjects excluded at each exclusion stage is summarised in
Figure 1.
Image acquisition and analysis
The ADNI MRI protocol used in this study is described
elsewhere [27]. Two T1-weighted MRI scans (MPRAGE) were
acquired at each session. The higher quality image (as assessed by
a single quality control centre) was selected. Pre-processing
corrections were then applied depending on the scanner manu-
facturer and head coil used: 1) correction for image geometry
distortion due to gradient non-linearity (gradwarp) [28], 2) B1
non-uniformity correction [29] and 3) intensity non-uniformity
correction (N3 histogram peak sharpening)[30]. After pre-
processing, the scans were additionally visually inspected at the
Dementia Research Centre for motion artefacts. Those scans with
significant motion artefacts were excluded from the current study.
Whole-brain and hippocampi were automatically delineated using
the Multi-Atlas Propagation and Segmentation technique (MAPS)
from the pre-processed 1.5-T T1-weighted MRI scans at all
available time-points [31,32]. The whole-brain MAPS technique
uses a template library of semi-automatically segmented whole-
brain regions (comprised of grey and white matter containing
voxels with the brain-stem included up until the most inferior slice
containing cerebellum) and the hippocampal MAPS technique
uses a template library of manually segmented hippocampal
regions. The MAPS technique works by comparing the target
image to these templates and the best-matched templates are then
combined to generate the segmentation of the target image. The
change in the volumes of the whole-brain and hippocampi
between follow-up and baseline were calculated using the robust
boundary shift integral (KN-BSI) [33]. Total intracranial volume
(TIV) was estimated by summing the volumes of grey matter,
white matter, and cerebrospinal fluid (CSF) segmentations using
SPM8 (http://www.fil.ion.ucl.ac.uk/spm/software/spm8). Brain-
to-TIV ratio was calculated by dividing the extracted whole-brain
volumes by the extracted TIVs. A list of the subjects and time
points included in the analysis can be found in appendix S1.
Statistical Analysis
All statistical analyses were performed in Stata (version 12).
APOE e4 carrier status was coded as 1 for carriers of 1 or 2 e4
alleles and 0 for those who did not carry an e4 allele. We analysed
the effect of APOE e4 carrier-status on the volume of the sum of
the left and right hippocampi at baseline adjusting for the level of
overall whole-brain atrophy. To do this a linear regression was
performed within each clinical group with bilateral hippocampal
volume as the dependent variable and APOE e4 carrier-status,
age, gender, MMSE score, TIV and brain-to-TIV ratio included
as covariates. Age was included as a covariate as normal aging is
associated with brain volume loss, TIV to control for variation in
head size and gender to control for any differences in male-to-
female ratio between the different genotype groups. We included
MMSE score and brain-to-TIV ratio as covariates in order to
assess the effect of the APOE e4 carrier-status above and beyond
any global differences in cognitive impairment and whole-brain
atrophy.
Disproportionate Hippocampal Atrophy in APOE e4
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To analyse the effect of the APOE e4 carrier-status on the rate
of atrophy of the hippocampi and whole-brain (as measured using
the BSI), joint linear mixed models were used. These models allow
the random-effects dictating the trajectories of hippocampal and
whole-brain atrophy to be correlated, thus permitting estimates of
hippocampal atrophy rate adjusted for true whole-brain atrophy
rate. They allow for repeated measures and accommodate missing
values under the missing at random assumption. The dependent
variables were the ml loss of hippocampi as calculated by the
hippocampal-BSI and brain as calculated by the brain-BSI.
Interval (years) between baseline and follow-up scans was
included as a fixed-effect and interactions terms between APOE e4
carrier-status and scan interval were included to allow hippocam-
pal atrophy rate to vary with APOE e4 carrier-status. Interactions
of interval with age, MMSE score, brain-to-TIV ratio, gender and
TIV (all measured at baseline) were also included as fixed-effects in
the model. Interval was also included as a random-effect, to allow
for between subject heterogeneity in atrophy rate. No constant
terms (fixed or random) were included, consistent with the
assumption that true (as opposed to measured) atrophy between
two scans from the same time-point is zero. A single joint model
was fitted to both hippocampal and whole brain losses, allowing
distinct fixed and random effect parameters for the two processes.
The two trajectories were linked through a correlation between the
two random slopes. The difference in mean hippocampal rates
between e4+ and e42 after adjustment for concurrent brain
atrophy rate was then estimated. This was calculated as the
difference in hippocampal rates (unadjusted for brain atrophy
rate), minus the difference attributable due to differences in brain
rates (based on the standard deviations of the random-slopes and
their correlation in the joint model). See appendix s2 for the
expressions of the statistical models used.
Since we included gender as a binary categorical variable in our
analyses we chose to present mean adjusted values for a 50/50
split of males: females in the Figures and Tables (adjusted for
disease-group specific mean age, baseline brain-to-total intracra-
nial volume ratio, MMSE score and total intracranial volume).
The mean adjusted values for a 50/50 gender split were calculated
by multiplying the coefficients for males and females by 0.5 and
adding them together. Given that we did not include an
interaction term between e4 carrier-status and gender in our
analyses, the differences in whole-brain and hippocampal atrophy
rates are the same for males and females.
Results
Table 1 shows demographics and imaging summary statistics for
each clinical group used in this study. As previously shown [31],
the AD subjects had smaller mean hippocampal volumes at
baseline than MCI subjects whose hippocampi were in turn
smaller than control subjects (Table 1); the mean hippocampal
volume for the AD subjects was ,20% smaller than the controls
with the MCI-P and MCI-S subjects having intermediate volumes.
Baseline cross-sectional results
Table 2 and Figure 2 show the results of the cross-sectional
analysis of hippocampal volumes. In AD, after adjustment for age,
gender, MMSE score, brain-to-TIV ratio and TIV, the mean
baseline hippocampal volume of e4+ was significantly smaller than
that of e4- (by ,8%). There was no evidence of a difference in
mean adjusted baseline hippocampal volume between e4 carriers
and non-carriers in MCI-P, MCI-S or controls.
Figure 1. Subject selection process.
doi:10.1371/journal.pone.0097608.g001
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Longitudinal Results
Table 3 and Figure 3, Figure 4 and Figure 5 show the results of
the longitudinal analyses of the differences in mean adjusted
atrophy rates between e4+ and e4- in all subject groups.
We found statistically significant evidence that in AD, MCI-P
and MCI-S subjects, after adjusting for age, gender, TIV, MMSE
score and brain-to-TIV ratio, the mean hippocampal atrophy
rates were higher in e4+ compared with e4- (see Figure 3). Mean
adjusted brain atrophy rates were also higher in e4+ compared
with e4-, but only significantly so in the MCI-S group (see
Figure 4). After adjustment for concurrent whole-brain atrophy,
the difference in atrophy rate between e4+ and e4-was reduced by
, 25% in AD, by ,40% in MCI-P and by ,75% in MCI-S (see
Figure 5). Although the differences in mean adjusted hippocampal
atrophy rates were reduced when additionally adjusting for
concurrent whole-brain loss, differences between e4+ and e4-
remained statistically significant in AD and MCI-P. In the control
group there was no evidence that hippocampal or whole-brain
atrophy rate differed between e4+ and e4- (p.0.8 for both).
Discussion
This study examined the effect of APOE genotype on
hippocampal volumes and hippocampal atrophy rates in AD,
MCI and in controls, with and without adjusting for concurrent
brain atrophy rates.
Cross-sectionally we found evidence that AD e4+ had smaller
(,8%) mean hippocampal volumes at baseline than e4- after
adjusting for age, TIV, gender, MMSE score and brain-to-TIV
ratio. There was no evidence that e4+ had smaller hippocampal
volumes than non-carriers in MCI-P, MCI-S or controls.
Longitudinally, we found evidence that mean adjusted hippo-
campal atrophy rates were higher in e4+ in AD, MCI-P and MCI-
S but not in controls. We also found evidence that mean adjusted
hippocampal atrophy rates were higher in e4+ in AD and MCI-P
after adjusting for concurrent whole-brain atrophy rates. The
difference in hippocampal atrophy rates in MCI-S was no longer
significant after adjustment for concurrent brain atrophy rate.
Taken together these results demonstrate that e4 carriers with a
clinical diagnosis of AD or of progressive MCI have a different
pattern of atrophy - disproportionately greater hippocampal loss -
than non-carriers. Cross-sectional studies have shown reduced
hippocampal volumes in e4+ compared with e4- in AD. However,
without investigating longitudinal changes in hippocampal vol-
ume, it is not possible to tell whether these findings could be
perhaps explained by developmental differences. Indeed, there is
evidence that there are some developmental differences with one
study reporting higher Mental Development Index scores in 24
month old babies who were e4+ compared with those who were
e42 [34]. There are few studies in healthy young people
comparing hippocampal volumes in e4+ and e42. One study in
a large cohort of adolescents reported no significant difference in
hippocampal volumes between e4+ and e42 [35] whilst another
smaller study in young adults reported significantly smaller
hippocampi in e4+ [36]. However, the study in adolescents did
not adjust for head size whilst the study in young adults did, which
makes comparisons between the studies difficult. Further studies
would be required to understand the developmental differences
between e4+ and e42.
In older adults previous longitudinal studies have reported
higher hippocampal rates in e4+ compared with e42. However,
higher rates of hippocampal atrophy in e4+ could be potentially
explained by higher rates of whole-brain atrophy (i.e. a more
aggressive disease course with a more rapid loss of whole-brain
tissue). In order to disentangle the effects of the e4 allele on global
and local hippocampal atrophy it is necessary to adjust hippo-
Table 1. Baseline demographics and image summary statistics by clinical group.
Controls MCI stable MCI progressors AD
No. Subjects (at 6 m, at 12 m, at 18 m, at 24 m, at 36 m) 167 (165, 153, 0,
137, 115)
169 (157, 147,
125, 103, 66)
138 (133, 131, 116,
102, 69)
148 (143, 124, 1,
93, 1)
No. e4 non-carriers (% total), No. e4 heterozygotes
(% total), No. e4 homozygotes (% total)
118 (71%), 44
(26%), 5 (3%)
86 (51%), 68 (40%),
15 (9%)
42 (30%), 70 (51%),
26 (19%)
44 (30%), 70
(47%), 34 (23%)
% male 54% 66% 59% 55%
Age [years] 76.0 (5.1) 75.5 (7.2) 74.2 (6.9) 75.0 (7.6)
MMSE score 29.2 (0.9) 27.2 (1.8) 26.6 (1.7) 23.4 (1.9)
TIV [cm3] 1548 (143) 1558 (142) 1552 (156) 1537 (167)
Unadjusted mean bilateral baseline hippocampal volume [cm3] 5.2 (0.7) 4.6 (0.8) 4.2 (0.8) 3.9 (0.9)
Age, TIV, MMSE and unadjusted hippocampal volume (left and right summed) are given as mean (SD).
doi:10.1371/journal.pone.0097608.t001
Figure 2. Effect of APOE e4 on baseline hippocampal volumes.*
doi:10.1371/journal.pone.0097608.g002
Disproportionate Hippocampal Atrophy in APOE e4
PLOS ONE | www.plosone.org 4 May 2014 | Volume 9 | Issue 5 | e97608
campal atrophy rates for global atrophy rates (whole-brain). In this
study we found that hippocampal atrophy rates were still higher in
e4+ in AD and progressive MCI following adjustment for whole-
brain atrophy rates. This suggests that higher hippocampal
atrophy rates found in e4+ are unlikely to be simply due to a
more aggressive disease with faster disease progression (as
measured by generalised brain tissue loss) alone. It may be that
AD associated with the e4 allele is a different anatomical disease to
AD without this allele, which should be considered when assessing
the effect of potentially disease modifying treatments.
Our finding of a lack of substantive differences between e4+ and
e42 in hippocampal volume and atrophy rate in healthy control
subjects is in agreement with some previous findings [15,16,21,24].
Conversely, a number of previous studies have reported increased
hippocampal atrophy rates for e4+ compared with e42 controls
[11–13,17,19,20,25,37,38]. However, inconsistencies in findings
between our study and that of some of the others may be due to
different recruitment strategies: some studies had less stringent
inclusion criteria than ADNI by including some MCI subjects with
controls [17,37]; some had a majority of subjects with a 1st degree
relative with a history of AD [12]. Differences in study design may
also explain inconsistencies: some studies measured atrophy over a
longer period, thus increasing the power with which to estimate
differences in atrophy rates [13,17,38]. In the largest longitudinal
study to date, with over 200 e4 heterozygotes, no evidence of a
difference in rates between heterozygotes and non-carriers was
found [13], consistent with our findings.
Interestingly, different studies using subsets of the controls in the
ADNI cohort have reported conflicting findings. Some reported
significant evidence of an association between APOE genotype
and bilateral hippocampal atrophy rate [11,20]. One study that
analysed the left and right sides separately reported a significantly
higher rate of hippocampal atrophy on the right side hippocampus
in e4+ compared with e42 [25] another reported a significantly
higher atrophy rate in the left hippocampi in e4+ compared to
e42 [19]. Others found no such association [16,21]. Differences
between findings of these studies and our own may be due to
inclusion of e2 carriers in most studies since e2 carriers have shown
lower hippocampal atrophy rates compared with non-carriers
[26].
Reported results in MCI subjects are also mixed; a number of
publications have shown a significantly greater hippocampal
Table 2. Adjusted mean baseline hippocampal volumes for e4 non-carriers and adjusted mean differences in total (left and right
summed) baseline hippocampal volumes between e4 carriers and non-carriers in controls, stable MCI, MCI progressors and AD (-ve
sign means e4+ , e4-).
Controls (e4- = 118,
e4+ = 49)
MCI-S (e4- = 86,
e4+ = 83)
MCI-P (e4- = 42,
e4+ = 96)
AD (e4- = 44, e4+ =
104)
Mean adjusted* baseline hippocampal volume** in e4- (cm3)
[95% CI]
5.19 [5.08, 5.29] 4.58 [4.44, 4.72] 4.19 [4.00, 4.39] 4.15 [3.93, 4.37]
Difference in mean adjusted* baseline hippocampal volume**
between e4+ and e4- (cm3) [95% CI]
20.02 [20.21, 0.16]
p = 0.811
20.06 [20.26, 0.13]
p = 0.508
20.03 [20.27, 0.20]
p = 0.772
20.33 [20.59, 20.07]
p = 0.015
* all values are for a 50/50 gender split and are adjusted for disease-group specific mean age, baseline brain-to-total intracranial volume ratio, MMSE score, and total
intracranial volume. **average of left and right.
doi:10.1371/journal.pone.0097608.t002
Figure 3. Effect of APOE e4 on hippocampal atrophy rates.*
doi:10.1371/journal.pone.0097608.g003
Figure 4. Effect of APOE e4 on whole-brain atrophy rates.*
doi:10.1371/journal.pone.0097608.g004
Disproportionate Hippocampal Atrophy in APOE e4
PLOS ONE | www.plosone.org 5 May 2014 | Volume 9 | Issue 5 | e97608
atrophy rate in e4+ compared with e42 [11,16,22,25]. One study
reported a significantly greater atrophy rate in the left hippocam-
pus [19]. Conversely other studies reported no significant
difference between e4+ and e42 in hippocampal atrophy rate in
MCI [21,24].
In the majority of the studies using data from ADNI an
association has been found between e4 carrier-status and higher
hippocampal atrophy rates in MCI much like our own study. This
is unsurprising in many ways since the MCI group has a high
proportion of subjects who will progress to clinical AD; these
subjects are more likely to be e4+ and more likely to have
increased hippocampal atrophy when compared with the MCI
subjects who remain stable and may be less likely to have
underlying AD pathology and less likely to be an e4 carrier.
Other studies have examined hippocampal atrophy rates in
MCI-S and MCI-P separately. One study, using voxel based
morphometry (VBM) found increased hippocampal atrophy rates
in MCI-P e4+ compared with e4- but not in MCI-S [22]. Another
study, which used a number of hippocampal measures, found
significantly higher rates in e4+ in all measures in the MCI stable
group [20]. In MCI-P they only found significantly increased loss
of hippocampal grey matter (GM) density and GM volume in e4+
but not hippocampal volume (as measured by FreeSurfer). We
found no evidence of a difference in hippocampal atrophy rates in
the MCI-S group after adjusting for concurrent whole-brain
atrophy rate.
Our finding in AD of smaller hippocampi in e4+ at baseline
compared with e42 is in keeping with a previous study which
reported evidence of a negative association between e4 dose and
normalised hippocampal volume in AD subjects when adjusting
for other covariates such as MMSE score [39]. Further, our
longitudinal findings in AD of increased hippocampal atrophy
rates in e4+ compared with e42 are in line with some previous
studies [16,18,21]. Other studies report mixed or negative results
for this comparison which may depend on the image analysis
methodology: one study reported increased hippocampal GM
atrophy in e4+ but no significant increase in hippocampal atrophy
(as measured with FreeSurfer) or GM density changes [20]; Others
found no significant difference in hippocampal loss rates between
e4+ and e42 in AD [11,15].
A strength of our study was the relatively large number of
subjects with data from multiple time-points (up to 36 months
from baseline). ADNI has the advantage of being a prospective
study with standardised follow-up times and high quality MRI
imaging. We used the MAPS hippocampal segmentation tech-
nique which has been shown to have good accuracy when
compared with manual segmentations [31]. In addition, the
Figure 5. Difference in hippocampal atrophy rates*: e4+ vs e4-.
doi:10.1371/journal.pone.0097608.g005
Table 3. Adjusted mean difference in whole-brain and hippocampal atrophy rate (ml) [95% CI] for e4 carriers compared with non-
carriers in controls, stable MCI, MCI progressors and AD (+ve means atrophy rate is higher in e4+).
e4 carrier
status
Controls (e42 =118,
e4+ = 49)
MCI stable
(e42 = 86,
e4+ = 83)
MCI progressors
(e42 = 42,
e4+ = 96)
AD (e42 = 44,
e4+ = 104)
Whole-brain Mean adjusted*
atrophy rate (ml/year)
e42 6.54 [5.88, 7.20] 7.91 [6.90, 8.93] 12.24 [10.47,
14.02]
14.11 [12.26, 15.96]
Difference in mean
adjusted* atrophy
rate (ml/year)
e4+ vs e42 0.05 [21.15 1.25]
p = 0.938
2.57 [1.14, 4.00]
p,0.001
1.62 [20.54,
3.77] p = 0.142
1.58 [20.65, 3.81]
p = 0.165
Hippocampus** Mean adjusted* atrophy
rate (ml/year)
e42 0.069 [0.058, 0.079] 0.102 [0.085,
0.120]
0.151 [0.125,
0.177]
0.173 [0.145, 0.200]
Difference in mean
adjusted* atrophy rate
(ml/year)
e4+ vs e42 0.001 [20.018, 0.021]
p = 0.881
0.036 [0.011,
0.061] p = 0.005
0.045 [0.014,
0.076] p = 0.004
0.043 [0.010, 0.076]
p = 0.011
Difference in mean
adjusted* atrophy
rate after adjustment for
concurrent whole-brain
atrophy rate (ml/year)
e4+ vs e42 0.001 [20.014, 0.016]
p = 0.897
0.013 [20.009,
0.036] p = 0.250
0.031 [0.006,
0.056] p = 0.014
0.029 [0.002, 0.057]
p = 0.037
* all values are for a 50/50 gender split and are adjusted for disease-group specific mean age, baseline brain-to-total intracranial volume ratio, MMSE score, and total
intracranial volume.
**average of left and right.
doi:10.1371/journal.pone.0097608.t003
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analysis method has the advantage of a robust and direct
longitudinal measure of hippocampal and whole brain change,
the BSI.
This study also has a number of limitations. First the ADNI
clinical diagnoses have not been pathologically confirmed and it
may be that some AD diagnoses will prove to be caused by non-
AD pathology at autopsy. Secondly, since our segmentation
method (hippocampal-MAPS) excludes the hippocampal tail, and
it is possible that atrophy rates differ across hippocampal sub-
regions, we could be potentially missing early changes in control
subjects positive for the e4 allele and including this region in all
subject groups may change the results. Thirdly, the longitudinal
model assumes that the missing observations were missing at
random, an assumption which cannot be empirically verified.
Finally, we excluded subjects with an e2 allele since we did not
want this to confound our results. It would be of particular interest
to investigate hippocampal atrophy rates in e2/e4 subjects as
compared with other genotypes to evaluate whether e2 or e4 has
greater influence on rates; however this genotype was rare in this
dataset (only 3 controls, 2 MCI-S, 5 MCI-P and 2 ADs had the
e2/e4 genotype).
In summary, we have investigated the association of hippocam-
pal volume and hippocampal atrophy rate with APOE genotype,
while adjusting for age, gender, cognitive impairment (MMSE
score), baseline atrophy level (brain-to-TIV ratio) and head size as
well as interval between scans in the longitudinal analysis. We
found evidence that within the AD group e4+ had lower mean
adjusted hippocampal volumes at baseline compared with e42.
We found evidence that AD, MCI-P and MCI-S e4+ had higher
mean adjusted hippocampal atrophy rates compared with e42
and furthermore that in AD and MCI-P e4 carriers still showed
higher mean adjusted hippocampal atrophy rates after adjustment
for concurrent whole-brain atrophy rates (which, to our knowl-
edge, has not be previously shown). Higher atrophy rates in e4+
suggest that the patterns of atrophy are not merely manifestations
of developmental differences according to genotype. Our results
thus support the hypothesis that in AD the e4 allele influences
disease phenotype with greater hippocampal involvement com-
pared with non-carriers.
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